A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer

This study investigated the maximum tolerated dose of S-1 based on the frequency of its dose-limiting toxicities (DLT) with concurrent radiotherapy in patients with locally advanced pancreatic cancer. S-1 was administered orally at escalating doses from 50 to 80 mg m(−2) b.i.d. on the day of irradia...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, M, Okusaka, T, Ito, Y, Ueno, H, Morizane, C, Furuse, J, Ishii, H, Kawashima, M, Kagami, Y, Ikeda, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359907/
https://www.ncbi.nlm.nih.gov/pubmed/17533388
http://dx.doi.org/10.1038/sj.bjc.6603788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359907/
https://www.ncbi.nlm.nih.gov/pubmed/17533388
http://dx.doi.org/10.1038/sj.bjc.6603788

Ejemplares similares